Blood test could decide cancer therapy

A blood test can determine whether prostate cancer patients are likely to respond to drugs, scientists say.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news

Related Links:

Treatment for prostate cancer with external beam radiotherapy was found to be associated with an increased risk for development of bladder cancer when compared with radical prostatectomy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
andez G Abstract Capsaicin (CAP) has been long known for its analgesic properties and more recently for its antitumor activity in various cell types. However, its pungency and the high doses needed to achieve a significant activity have precluded its application in cancer therapy. Herein, we propose a straightforward novel strategy to improve the antitumor effect of CAP based on the enhancement of its aggregation propensity in aqueous media by covalent attachment of a BODIPY (BDP) dye. The target CAP-BDP 1 self-assembles in aqueous solutions into weakly fluorescent globular assemblies that become highly emissive u...
Source: Angewandte Chemie - Category: Chemistry Authors: Tags: Angew Chem Int Ed Engl Source Type: research
CONCLUSIONS: Compared to ADT alone, the early (within 120 days of beginning ADT) addition of taxane-based chemotherapy to ADT for hormone-sensitive prostate cancer probably prolongs both overall and disease-specific survival and delays disease progression. There may be an increase in toxicity with taxane-based chemotherapy in combination with ADT. There may also be a small, clinically unimportant improvement in quality of life at 12 months with taxane-based chemotherapy and ADT treatment. PMID: 30320443 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
CONCLUSION: The present study showed that miR-let7b and/or mir-548 can be considered as potential targets in prostate cancer therapy. PMID: 30318571 [PubMed - as supplied by publisher]
Source: Urology Journal - Category: Urology & Nephrology Authors: Tags: Urol J Source Type: research
UCLA researchers have discovered  genetic similarities between the adult stem cells responsible for maintaining and repairing epithelial tissues — which line all of the organs and cavities inside the body — and the cells that drive aggressive epithelial cancers. Their findings could bring about a better understanding of how ag gressive, treatment-resistant cancers develop and progress, and could eventually lead to new drugs for a range of advanced epithelial cancers such as lung, prostate and bladder cancers. The study, led by senior authors Owen Witte and Thomas Graeber, both of the  UCLA E...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
CONCLUSION: Our findings provide evidence of the clinical relevance, significance and regulation of HSD17B2 in prostate cancer progression, which might provide new strategies for clinical management by targeting the functional silencing mechanisms of HSD17B2. PMID: 30228209 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Publication date: Available online 10 September 2018Source: Seminars in Cancer BiologyAuthor(s): Nicholas Howard, Marco Clementino, Donghern Kim, Lei Wang, Angela Verma, Xianglin Shi, Zhuo Zhang, Robert S. DiPaolaAbstractProstate cancer is the most prevalent type of cancer in men. The etiology of prostate cancer development and the mechanisms underlying androgen-independent progression remains to be further investigated. There are many known targets for prostate cancer therapy including the androgen receptor (AR) axis, but resistance eventually develops in advanced disease suggesting the need to better understand mechanism...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Our result demonstrated the in vitro and in vivo antimetastatic effect of pan-PI3K inhibitor ZSTK474 on prostate cancer DU145 cells, suggesting the potential application in prostate cancer patients. PMID: 30205797 [PubMed - as supplied by publisher]
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research
Alpha Tau Medical said today it raised $29 million in a private funding round to help support its alpha radiation cancer therapy technology. The round was led by Israeli private equity firm Shavit Capital and joined by global equity crowdfunding platform and Medison Pharma venture capital arm Medison Ventures, the Israel-based company said. The round was also joined by Apax Partner founds Ronald Cohen and Alan Patricof, Alpha Tau said. “We are confident that Alpha Tau’s ground-breaking technology can be a game changer in the treatment of cancer. Importantly, under the guidance of an exper...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Funding Roundup Alpha Tau Medical Source Type: news
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer remains largely incurable even after intensive multimodal therapy. The lethality of advanced disease is driven by the lack of therapeutic regimens capable of generating durable responses in the setting of extreme tumor heterogeneity on the genetic and cell biological levels. Here, we review available prostate cancer model systems, the prostate cancer genome atlas, cellular and functional heterogeneity in the tumor microenvironment, tumor-intrinsic and tumor-extrinsic mechanisms underlying therapeutic resistance, and technological a...
Source: Genes and Development - Category: Genetics & Stem Cells Authors: Tags: Cancer and Disease Models Reviews Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Prostate Cancer